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Objectives: In the light of increasing drug resistance in Staphylococcus aureus, bacteriophage endolysins
[peptidoglycan hydrolases (PGHs)] have been suggested as promising antimicrobial agents. The aim of this
study was to determine the antimicrobial activity of nine enzymes representing unique homology groups within
a diverse class of staphylococcal PGHs.
Methods: PGHs were recombinantly expressed, purified and tested for staphylolytic activity in multiple in vitro
assays (zymogram, turbidity reduction assayand plate lysis) and against a comprehensive set of strains (S. aureus
and CoNS). PGH cut sites in the staphylococcal peptidoglycan were determined by biochemical assays (Park–
Johnson and Ghuysen procedures) and MS analysis. The enzymes were tested for their ability to eradicate static
S. aureus biofilms and compared for their efficacy against systemic MRSA infection in a mouse model.
Results: Despite similar modular architectures and unexpectedly conserved cleavage sites in the peptidoglycan
(conferred by evolutionarily divergent catalytic domains), the enzymes displayed varying degrees of in vitro lytic
activity against numerous staphylococcal strains, including cell surface mutants and drug-resistant strains, and
proved effective against static biofilms. In a mouse model of systemic MRSA infection, six PGHs provided 100%
protection from death, with animals being free of clinical signs at the end of the experiment.
Conclusions: Our results corroborate the high potential of PGHs for treatment of S. aureus infections and reveal
unique antimicrobial and biochemical properties of the different enzymes, suggesting a high diversity of potential
applications despite highly conserved peptidoglycan target sites.
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Introduction
Staphylococcus aureus is a Gram-positive bacterial pathogen
responsible for mortality and morbidity in both humans and
animals worldwide. It is an important foodborne pathogen and
a major cause of nosocomial infections, generating excessive
healthcare costs and associated with a wide array of diseases.1
Besides its role as a human pathogen, S. aureus has high impact
on the dairy industry (annual loss of$2 billion in the USA) as the
major causative agent of bovine mastitis.2 S. aureus is also
capable of producing biofilms,3 which are a persistent problem
in medicine, food safety and agriculture.4,5 In both human clinics
and agricultural settings, MDR S. aureus strains are becoming
increasingly prevalent.6,7 MRSA accounts for up to 60% of
hospital- and community-acquired S. aureus infections.8,9 For
this reason, alternative therapeutics for treatment of S. aureus
infections are urgently needed.
Endolysins are bacteriophage-encoded peptidoglycan (PG)
hydrolases (PGHs) that are produced inside an infected host cell
at the end of the phage lytic cycle to enzymatically degrade the
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bacterial PG ‘from within’, resulting in cell lysis and liberation
of progeny phages. In Gram-positive bacteria, which lack an
outer membrane, lysis can also be achieved ‘from without’, by
exogenously applying (recombinant) endolysins. Therefore,
these enzymes have attracted increasing attention as potential
antimicrobials in recent years.10,11 Development of resistance to
endolysins is believed to be rare compared with antibiotics
because of their target cell specificity, their highly conserved tar-
gets in the PG,10 and because their application ‘from without’
avoids many possible resistance mechanisms.12 While various
studies have unsuccessfully attempted to generate endolysin-
resistant strains,10 resistance against non-endolysin PGHs, such
as lysostaphin,13 has been reported. This bacteriocin targets the
weakly conserved pentaglycine cross-bridge,14 modification of
which has been shown to cause lysostaphin resistance in several
strains.15 Endolysins from a Gram-positive background show a
modular design, consisting of enzymatically active domains (EADs)
and cell wall binding domains (CBDs).16 CBDs confer specificity by
recognizing certain cell wall ligands, whereas EADs catalyse PG deg-
radation. The EADs can be classified with regard to their cleavage
sites in the PG, with glycosidases, amidases and endopeptidases
cutting within the sugar strand, between sugar and peptide
moieties, and within the peptide portion, respectively. Endolysin
architectures found in public databases are diverse regarding
the number and arrangement of individual domains.4
The largest subgroup of staphylococcal PGHs feature C-terminal
SH3b CBDs17 and, in most cases, two different EADs [N-terminal
cysteine, histidine-dependent amidohydrolase/peptidase (CHAP)
and centrally located N-acetylmuramoyl-L-alanine amidase], as
predicted by bioinformatics.4,18 PG cut sites have been determined
only for the endolysins of the phages K (LysK) and phi11 (phi11).
Both cleave the MurNAc-L-Ala amide bond (amidase) and the
D-Ala-Gly bond between the stem peptide and the pentaglycine
bridge (CHAP).19,20 SH3b-bearing staphylococcal PGHs fall into five
homology groups that show .90% within-group and ,50%
between-group sequence identity, and six ‘stand-alone’ proteins
(it should be noted that the SH3b domain corresponds to the region
of highest sequence conservation between the different groups).18
Some of these highly diverse enzymes have been partially charac-
terized.19–25However, comparison of results from different labora-
tories is hampered by the multitude of methods and assay
conditions used.11
Here, we comparatively characterized nine different recombin-
ant PGHs representing all of the homology groups mentioned
above and four stand-alone proteins. This analysis included deter-
mination of (i) lytic activity by multiple in vitro assays and against
various staphylococcal strains; (ii) cleavage sites in the PG;
(iii) anti-biofilm activity; and (iv) therapeutic potential using a
mouse model of systemic MRSA infection.
Materials and methods
Constructs, plasmids and strains
The nucleotide sequences encoding the endolysins of the staphylococcal
phages phi80a (80a; GenBank accession number ABF71642.1), phi11
(phi11; YP_500516.1), K (LysK; YP_024461), phiP68 (P68; NP_817332.1)
and Twort (Twort; AAX92311) were kindly provided by G. Christie,26
R. Jayaswal,27 P. Ross,28 U. Bla¨si29 and M. Loessner,25 respectively. The
phage 2638A endolysin (2638A; AAX90995) gene was amplified
from S. aureus 2854 (HER 1283, Laval University, Quebec, Canada).22
Sequences of the Staphylococcus haemolyticus prophage phiSH2
(phiSH2; BAE05642.1)23 and the Staphylococcus warneri phage phiWMY
(WMY; BAD83402)24 endolysins were synthesized (GeneArt, Regensburg,
Germany). The sequence coding for mature lysostaphin (P10547) was a
gift from David Kerr.30 All sequences were inserted into NdeI and XhoI
restriction sites of pET21a (EMD Biosciences, San Diego, CA) using standard
molecular techniques, thereby adding 6×His-tag coding sequences to
the 3′ end of each gene (yielding C-terminally 6×His-tagged proteins).
Alternatively, N-terminally His-tagged versions were created by inserting
the coding sequences into BamHI and SalI sites of pQE30 (Qiagen,
Hilden, Germany). Unless stated otherwise, the C-terminally 6×His-tagged
constructs were used for experiments in this study. Escherichia coli BL21
(DE3) or XL1-Blue MRF′ (for pQE30-based constructs) was used for
overexpression of recombinant proteins and was grown in LB medium at
378Cwith 150 mg/L ampicillin for plasmid selection (+30 mg/L tetracycline
in the case of XL1-Blue MRF′). Staphylococcal strains used in this study are
listed in Table 1. They were grown in tryptic soy broth (TSB) or brain heart
infusion (BHI) at 378C, supplemented with suitable antibiotics if required.
Protein expression and purification
Expression and purification of recombinant 6×His-tagged PGHs was
performed essentially as previously described,31 with the following modi-
fications. Induced E. coli cultures were harvested, resuspended in 10 mLof
lysis buffer (50 mM NaH2PO4/300 mM NaCl/10 mM imidazole/30% gly-
cerol, pH 8.0) per 1 L of culture and sonicated on ice for 5 min (1 s pulses
separated by 1 s rests). After removal of debris by centrifugation (9000 g
for 30 min), 6×His-tagged proteins were purified from the cleared super-
natant by immobilizedmetal ion affinity chromatography using nickel-NTA
Superflow resin (Qiagen, Valencia, CA, USA). When proteins were prepared
for in vivo experiments, purification columns were washed with 25 column
volumes (CV) of lysis buffer supplemented with 0.1% Triton X-114 for
removal of endotoxin,32 40 CV of lysis buffer and 15 CV of wash buffer
(50 mM NaH2PO4/300 mM NaCl/20 mM imidazole/30% glycerol, pH 8.0).
For all other experiments, the Triton X-114washwas omitted and columns
were washed with 25 CV of lysis buffer and 15 CV of wash buffer instead.
Target proteins were eluted with elution buffer (50 mM NaH2PO4/300 mM
NaCl/250 mM imidazole/30% glycerol, pH 8.0) in 500 mL fractions.
Fractions with high protein concentrations were combined and, in the
case of in vivo experiments, dialysed against dialysis buffer [50 mM
NaH2PO4/300 mM NaCl/10% glycerol (20% in the case of P68), pH 7.5].
Proteins were filtered (0.2 mM), concentrations were measured spectro-
photometrically using a NanoDrop ND-1000 (NanoDrop Technologies,
Wilmington, DE, USA) and purity was determined by SDS–PAGE. In the
case of C-terminally 6×His-tagged 2638A (for which purification yields a
double band), the concentration was determined based on the estimation
that the full-length endolysin accounts for 50% of the total protein
amount (Figure 1). Representative random samples were evaluated for
endotoxin content using the Limulus amoebocyte lysate assay (LAL
QCL-1000, Lonza, Walkersville, MD, USA) and shown to be ,5 EU/mg.
SDS–PAGE and zymogram
SDS–PAGE and zymogram analyses of purified staphylococcal PGHs were
carried out as described previously,33 using 15% or 12% polyacrylamide
gels and Kaleidoscope Precision Plus Protein Standard (Bio-Rad). For the
zymogram, a 300 mL culture volume equivalent of live mid-log phase
(OD600¼0.4–0.6) cells of S. aureus strain Newman was embedded in the
gel during polymerization. After electrophoresis, zymogramswerewashed
extensively with water to remove SDS and enable re-folding of proteins,
followed by incubation in 10 mM Tris/150 mM NaCl, pH 8.0, for 30 min
and then 10 mM Tris/300 mM NaCl, pH 8.0, for another 30 min.
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Turbidity reduction assay
Turbidity reduction assays for quantification of enzymatic activity were
performed in a 96-well plate format essentially as described by Becker
et al.,19 using frozen but viable cells of S. aureus Newman as substrate.
In brief, equimolar concentrations (0.2 mM) of PGHwere added to bacterial
suspensions adjusted to an OD600 of 1.0 in 10 mM Tris/200 mM NaCl, pH
7.5, and the OD was measured at 20 s intervals for 30 min. The steepest
slopes of the resulting lysis curves were used for calculation of specific lytic
activities, which were expressed as DOD600 min
–1 mM–1. In order to
determine the effect of ionic strength on lytic activity, assays were carried
out as described above with varying NaCl concentrations, ranging from 0
to 600 mM. All assays were performed in triplicate.
Plate lysis assay
For plate lysis assays, the Staphylococcus strains listed in Table 1 were
grown to mid-log phase, diluted to an OD600 of 0.1 using PBS and 3 mL
of the suspension was spread on gridded tryptic soy agar (TSA) plates.
Excess liquid was removed and the plates were air dried for 15 min in a
laminar flow hood. Equimolar amounts (100, 10 and 1 pmol) of PGHs in
10 mL volumes were spotted onto the plates; the plates were air dried
for 10 min and then incubated overnight at 378C. Cleared spots within
the resulting bacterial lawn indicating cell lysis were scored within 24 h.
Plate lysis assays were performed in duplicate.
Biochemical assays for PGH cut site analysis
Preparation of crude cell walls from S. aureus strain SA113 was performed
as published earlier.34 Free amino groups in the peptidoglycan were
acetylated with acetic anhydride.35 Pre-acetylated cell walls were washed
three times with water and stored at –208C for endolysin activity assays.
Cell wall digestion was performed in 20 mM NaH2PO4/200 mM NaCl, pH
7.4, in a total volume of 100 mL containing cell walls (400 mg) and enzyme
(10 mg of P68, 2638A, 80a, Twort, WMY or mutanolysin). Mixtures were
incubated at 308C for 16 h and finally boiled at 1008C for 10 min to stop
reactions.
For reducing sugar analysis, digests were assayed by a modified Park–
Johnson method.36,37 A 10 mL aliquot of digested PG was mixed with
90 mL of water, 200 mL of 0.05% (w/v) potassium ferricyanide (in water)
and 200 mL of 0.53% (w/v) sodium carbonate/0.065% (w/v) potassium
cyanide (in water) and heated at 1008C for 15 min. Reactions were cooled
and 1 mL of ferric iron solution [0.15% (w/v) ferric ammonium sulphate,
0.1% (w/v) SDS in 0.025 M sulphuric acid] was added. After 10 min of
incubation, absorbance was measured at 690 nm. Undigested cell walls
were used as control. The content of reducing groups was calculated
using a calibration curve of glucose.
The liberation of free amino acids was determined by a modified
Ghuysen procedure using 1-fluoro-2,4-dinitrobenzene (FDNB).38 Enzymes
(10 mg) were added to each cell wall digest and themixturewas incubated
for 6 h at 378C for complete cell wall degradation. After inactivation at
1008C for 15 min, 15 mL of 10% K2B7O4 and 15 mL of FDNB solution
(0.1 M in ethanol) were added to the sample. The mixture was incubated
at 658C for 45 min in the dark. After hydrolysis with 4 M HCl (800 mL, 12 h
at 958C), the DNP amino acid derivatives were measured at 365 nm.
L-Alanine was used as the standard for calculations. All experiments
were performed in triplicate.
MS analysis of digested S. aureus cell walls
For determination of PGH cut sites within the staphylococcal PG, cell
walls were prepared and digested with the respective enzymes (the
N-terminally 6×His-tagged version was used in the case of 2638A) and
purified, and the resulting fragments were analysed by MS essentially as
described before.19,39 In brief, cell walls of strain Newman or SA113
DtagO were digested at 378C for 2 h with the respective enzymes, filtered
through 5000 MW cut-off Vivaspin 500 U (Sartorius North America Inc.,
Bohemia, NY, USA) and PG fragments were desalted using Sep-Pak C18
cartridges (Water Corporation, Milford, MA, USA). The eluted fragments
(in 50% methanol) were dried in a SpeedVac, dissolved in deionized
water and analysed by positive-ion electrospray ionization MS performed
on a Micromass Q-TOF2 device (Micromass Ltd, Manchester, UK). For exact
determination of endopeptidase cut sites, double digests with full-length
parental enzymes and a truncated version of LysK containing only the
CHAP domain19 were performed. For digests with P68, a double digest
was performed (with both P68 and an N-terminal truncation of 2638A
comprising only the amidase and SH3b domains22) in order to seewhether
the added amidase activity was able to reproduce the ions created
with the dual lytic domain endolysins. Fragments were filtered as
described above and desalted using C18 ZipTips (Millipore, Zug,
Switzerland), from which they were eluted with 10 mL of 50 :50:0.01
(v/v/v) CH3OH:H2O:HCOH (pH 2). NanoESI–MS analysis of the samples
was performed on a Q-TOF Ultima API mass spectrometer (Micromass,
UK). The solutions were infused through a fused silica capillary [internal
diameter (ID) 75 mm] at a flow rate of 0.50 mL/min. Electrospray Pico
Tips (ID 30 mm) were obtained from New Objective (Woburn, MA). Mass
spectra were acquired by scanning an m/z range from 50 to 3000 with a
scan duration of 1 s and an interscan delay of 0.1 s. Spray voltage was set
to 2.1 kV, cone voltage to 35V, RF lens 1 energy to 50 V and collision
to 10 eV.
Biofilm reduction assay
A method modified from previous studies40,41 was used to test the effect
of PGHs on staphylococcal biofilms in a static 96-well plate (polystyrene;
SPL Life Sciences, Korea)-based model. S. aureus SA113 was grown in
TSB+0.25% D(+)-glucose at 378C overnight, diluted 1/200 in the same
fresh medium, aliquoted in a 96-well plate (200 mL per well) and further
incubated for 24 h for biofilm growth. Biofilms were washed twice with
PBS. Serial dilutions of PGHs in elution buffer (70 mL per well) were
added and the plate was incubated at 378C for 2.5 h. Buffer alone served
as control. Afterwashing twicewith PBS, biofilmswere stainedwith 100 mL
of 0.4% crystal violet for 15 min at room temperature, followed by wash-
ing three times with PBS. The stain was dissolved in 33% acetic acid in
water and the OD590 of each well diluted 1/10 in water was measured
spectrophotometrically. Similar experiments were carried out in parallel
using N-terminally His-tagged versions of the enzymes and PBS for prep-
aration of enzyme dilutions. All experiments were performed in triplicate.
Mouse model for evaluation of PGHs against
MRSA in vivo
Female BALB/c mice aged 4–6 weeks (weight range 22–24 g, Harlan
Laboratories, Frederick, MD, USA) were used in biosafety level 2 facilities
in accordance with the University of Maryland institutional animal care
and use committee (College Park, MD, USA) regulations and national ani-
mal care guidelines. Briefly, MRSA strain NRS382 was grown overnight in
BHI medium at 378C. The culture was then diluted 1:100 and grown to
OD600¼0.3–0.4, centrifuged and resuspended in BHI supplemented
with 5% mucin (Sigma-Aldrich, St Louis, MO, USA) for the mouse experi-
ment, according to a previously reported protocol.42 The mouse model
was designed to be an LD90 model, i.e. to yield lethality in 90% of control
mice at the 48 h post-infection endpoint. To this end,4×107 cfu bacteria
in suspension (in a volume of 0.2 mL) were injected intraperitoneally.
Actual inoculum titres were derived by plating serial dilutions of each
inoculum on BHI agar plates.
To determine the in vivo efficacy of PGHs, 30 min post-infection,
infected mice were divided into groups (10 mice per group) and injected
intraperitoneally with either PGHs in dialysis buffer (200 mg/mouse
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in 200 mL) or PBS or dialysis buffer as controls (200 mL/mouse). The anti-
biotics vancomycin and oxacillin (Sigma-Aldrich), prepared in distilled H2O,
were used as additional controls. Antibiotics were administered subcuta-
neously (vancomycin, 375 mg/mouse; oxacillin, 1250 mg/mouse) 30 min
post-infection. The administration route and diluent most appropriate
for each therapeutic was chosen for these experiments. While subcutane-
ous administration and use of water as diluent is recommended for anti-
biotics, a phosphate buffer (dialysis buffer) was used for diluting PGHs to
avoid possible aggregation of the proteins in water, and intraperitoneal
administration of PGHs was chosen since it is well documented in the
literature.10 Oxacillin served as negative control for the subcutaneous
route of administration.
The survival rate for each experimental group was monitored every 4 h
up to 48 h post-bacterial challenge. The data were statistically analysed
using Kaplan–Meier survival curves and Fisher’s exact test. In addition, a
septicaemia score index described by Biswas et al.43 was used to evaluate
the health condition of MRSA-infected mice at intervals of 4 h for up to
48 h (Figure 5c).
To detect bacteria in the bloodstream, mice surviving until the end of
the experiment (48 h post-infection) were euthanized and 100 mL blood
samples were taken, mixed with 900 mL of PBS and then serially diluted
and plated on BHI agar plates.
Results
Staphylococcal PGHs from five different homology
groups kill S. aureus in vitro
Nine staphylococcal PGHs (Figure 1a) were expressed in E. coliwith
C-terminal 6×His-tags and purified by nickel affinity chromatog-
raphy, yielding preparations of .95% purity as demonstrated by
SDS–PAGE (Figure 1b). Purification of 2638A yielded a shadow
band at 36.3 kDa in addition to the expected 56.6 kDa band,
this has been shown to be due to a secondary translational
start site within the 2638A coding sequence22 that was not pre-
sent when the enzymewas purified with an N-terminal 6×His-tag
(Figure S1, available as Supplementary data at JAC Online).
Zymogram analysis revealed staphylolytic activity of all purified
enzymes, as apparent from cleared zones of lysis within the opa-
que gel containing S. aureus Newman cells (Figure 1c). While
intensities of clearing zones differed between enzymes (with
phiSH2 and 80a yielding barely visible and lysostaphin and P68
the most intense bands), the zymograms demonstrated that
the major bands corresponding to the target proteins accounted
for 98% of the activity within the preparations, whereas minor
contaminating bands (as visible on the SDS gel) contributed little
or no activity. Lytic activity of the nine PGHs was further analysed
by two quantitative PGH activity assays, turbidity reduction and
plate lysis. Despite their mostly conserved modular architecture,
the enzymes displayed vastly different degrees of specific activity
[DOD600 min
–1mM–1 ranging from ,0.1 (phiSH2) to 1.3 (LysK)]
against live bacteria in suspension (Figure 1d). Also, optimum
salt concentrations differed among the enzymes. While some
PGHs (phi11, 2638A, WMY) exhibited pronounced optima at
100 mM NaCl, others (LysK, phiSH2) were most active at higher
ionic strength (300–400 mM NaCl) (Figure 2 and Figure S2). It
is of note that lysostaphin, a well-characterized potent anti-
staphylococcal protein, showed onlymoderate activity in turbidity
reduction assays compared with other PGHs. In contrast, lysosta-
phin was clearly the most active enzyme in the plate lysis assay
(Table 1 and Figure S3A). When tested against the Newman strain,
it caused a lysis zone at the lowest concentration used (1 pmol per
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Figure 1. Modular organization, purification and staphylolytic activity of nine different staphylococcal SH3b domain-containing PGHs. (a) Schematic
representation of nine PGHs representing different homology groups reported previously.18 EADs are depicted as hatched and white/dotted bars and
SH3b CBDs as black bars. The scale indicates amino acid (AA) positions. M23, M23 endopeptidase domain; SH3b, bacterial SH3 domain (CBD). All proteins
harbour a C-terminal 6×His-tag (not represented). (b) SDS–PAGE of 6×His-tagged PGHs purified by immobilizedmetal ion affinity chromatography; 5 mg
of protein was loaded in each lane. Expected molecular weights: 80a, 54.9 kDa; phi11, 55.1 kDa; LysK, 55.8 kDa; P68, 29.6 kDa; lysostaphin, 28.2 kDa;
2638A, 56.6 kDa; Twort, 54.3 kDa; phiSH2, 57.4 kDa; andWMY, 55.0 kDa. Note that C-terminally 6×His-tagged 2638A purification yielded a double band
(for an explanation see the text). (c) Zymogramwith the enzymes shown in (b) and S. aureus Newman cells embedded in the gel. The same amounts of
protein as in SDS–PAGEwere loaded. (d) Specific activity of the nine PGHs against S. aureusNewman determined by turbidity reduction assays performed
with 0.2 mM enzyme in buffer containing 200 mM NaCl. Error bars indicate standard deviations from three independent experiments.
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10 mL spot), whereas at least 10 pmol/10 mL was required for
other PGHs.
PGH activity against multiple S. aureus strains and CoNS
To further elucidate their therapeutic potential, the lytic activity of
the nine PGHs was determined in plate lysis assays against a com-
prehensive collection of staphylococcal strains, including strains
relevant to clinical and agricultural settings, such as MRSA
strains, bovine mastitis isolates (S. aureus strains 305 and
SA001–SA04944) and CoNS. Furthermore, various mutant strains
with altered surface structures were tested, including mutants
lacking wall teichoic acids (DtagO45) or devoid of D-alanine in
the teichoic acids (DdltA46); mutants lacking the ability to produce
poly-N-acetyl-glucosamine, a surface polysaccharide often asso-
ciated with biofilm formation (Dica47); an srtA mutant of strain
Newman (lacking cell wall-associated proteins48); strains with
mutations in sarA, a global regulator of virulence factors, resulting
in increased protease secretion (MN8 DsarA, ALC134247); strains
with reduced susceptibility to lysostaphin (4-fold higher MIC com-
pared with the WT Newman strain), including a femAB mutant
having mono- instead of pentaglycine bridges (ANG133) and a
lyrA mutant with as yet uncharacterized cell wall alterations
(ANG144);15 and isogenic mutants expressing different capsular
polysaccharides or no capsule [Reynolds (CP5), Reynolds (CP8)
and Reynolds (CP2)49]. With the exception of phiSH2 and
2638A, most PGHs exhibited strong antimicrobial activity against
all or themajority of the strains (Table 1). As previously reported,22
2638A produced ill-defined lysis zones that increased in diameter
and intensity when incubated for extended periods of time
(Figure S3B). Most PGHs showed enhanced activity against tagO
mutants in both Newman and SA113 genetic backgrounds
(Figure S3A). By contrast, reduced activity was observed for all
enzymes against ANG144 compared with the Newman WT,
whereas the femABmutation (ANG133) showed reduced suscep-
tibility to lysostaphin but only minor changes in susceptibility to
the other PGHs.
Dual lytic domain endolysins have conserved PG cut sites
Bioinformatic analysis of the dual lytic domain endolysins (80a,
phi11, LysK, 2638A, Twort, phiSH2 and WMY) predicted similar
modular architectures (except for 2638A, which harbours an
M23 instead of a CHAP domain) (Figure 1a), suggesting similar
ontology and thus shared cleavage mechanisms. The absence
of reducing groups in the Park–Johnson chemical assay36 per-
formed with 80a, P68, 2638A, Twort and WMY on purified
S. aureus PG indicated that none of the enzymes yielded detect-
able glycosidase activity, as opposed to themuramidasemutano-
lysin50 (Table S1). In a modified Ghuysen assay, which detects
endopeptidase or amidase activity, mutanolysin yielded only
low (,0.1 mM) concentrations of free amino groups, whereas
P68 (harbouring one catalytic domain) and the dual lytic domain
endolysins produced 0.5 and 1 mM of free amino groups,
respectively (Table S1). When S. aureus cell walls digested with
80a, Twort or WMY were subjected to electron spray ionization
MS (ESI–MS), a dominant peak at m/z¼702 was observed. This
peak was identical to the one detected after LysK digestion
(Figure 3a), corresponding to the fragment Ala2-iGln-Lys-Gly5
produced by simultaneous action of a MurNAc-L-Ala amidase
and a D-Ala-Gly endopeptidase19 (Figure 3c). Surprisingly, diges-
tion with 2638A (N-terminally 6×His-tagged) yielded the same
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Figure 2. Comparison of lytic activity of nine PGHs against live S. aureus cells at varying ionic strength. Specific activity was determined by turbidity
reduction assays using 0.2 mM enzyme against S. aureus Newman cells suspended in Tris buffer, pH 7.5, with NaCl concentrations ranging from 0 to
600 mM. All assays were performed in triplicate. For graphs of individual enzymes with error bars, see Figure S2.
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Table 1. Activity of purified PGHs against multiple staphylococcal strains as determined by plate lysis assay
Straina Sourceb 80a Phi11 LysK P68 Lysostaphin
2638Ac
Twort PhiSH2 WMYday 1 day 3+
Newman 1 ++d ++ ++ + +++ 2 2 ++ 2 (+)
305 (Newbould) 2 ++ ++ ++ ++ +++ 2 2 ++ + ++
Newman smr 1 ++ ++ ++ ++ +++ 2 2 ++ (+) +
Newman DtagO 1 +++ +++ ++ ++ +++ +++ +++ ++ + +++
Newman Dica 1 ++ ++ ++ + +++ 2 2 ++ 2 (+)
Newman DdltA 1 ++ ++ ++ + +++ 2 2 ++ 2 +
Newman DsrtA 1 ++ ++ ++ + +++ 2 2 + 2 +
MN8 3 ++ ++ ++ + ++ 2 ++ + (+) +
MN8 Dica 3 ++ ++ ++ + ++ 2 ++ ++ 2 +
MN8 DsarA 3 ++ ++ ++ + ++ (+) +++ ++ 2 +
ALC 1342 4 ++ + ++ + ++ 2 2 ++ (+) (+)
ANG 133 5 ++ ++ + + ++e 2 2 + 2 (+)
ANG 144 5 (+) (+) + (+) ++e 2 2 + 2 2
SA113 6 ++ ++ ++ + +++ + ++ ++ 2 ++
SA113 DtagO 6 ++ +++ ++ ++ +++ +++ +++ ++ 2 +++
SA113 DdltA 6 ++ ++ ++ ++ +++ + ++ ++ + ++
Reynolds (CP–) 1 ++ ++ ++ + +++ 2 2 ++ (+) +
Reynolds (CP5) 1 ++ ++ ++ ++ +++ 2 2 ++ (+) ++
Reynolds (CP8) 1 ++ ++ ++ ++ +++ 2 2 ++ (+) +
NRS 382 (MRSA) 7 ++ + ++ + ++ 2 2 + (+) (+)
NRS 383 (MRSA) 7 ++ ++ ++ + +++ (+) ++ ++ + +
NRS 384 (MRSA) 7 ++ ++ ++ + +++ 2 (+) + (+) +
NRS 385 (MRSA) 7 ++ ++ ++ + +++ 2 2 ++ (+) +
SA001 8 ++ ++ ++ ++ +++ 2 2 ++ (+) ++
SA002 8 ++ ++ ++ ++ +++ 2 + ++ (+) +
SA003 8 ++ ++ ++ ++ +++ 2 2 ++ (+) +
SA009 8 ++ ++ ++ ++ +++ 2 2 ++ + ++
SA019 8 ++ ++ ++ ++ +++ 2 + ++ (+) (+)
SA020 8 ++ ++ ++ ++ +++ 2 + ++ + +
SA021 8 ++ + ++ + ++ 2 (+) + (+) (+)
SA026 8 ++ ++ ++ ++ ++ 2 + ++ (+) +
SA028 8 ++ + ++ + ++ 2 2 + (+) (+)
SA029 8 ++ ++ ++ ++ ++ (+) + ++ (+) ++
SA031 8 ++ ++ ++ + ++ 2 2 ++ (+) +
SA033 8 ++ ++ ++ + ++ 2 + ++ (+) ++
SA047 8 ++ ++ ++ + ++ 2 (+) ++ (+) +
SA048 8 ++ ++ ++ + ++ 2 + ++ (+) +
SA049 8 ++ ++ ++ + ++ 2 + ++ (+) ++
S. chromogenes 9 +++ +++ +++ +++ +++ + ++ ++ + ++
S. epidermidis 9 ++ (+) ++ + ++ 2 + ++ + 2
S. hyicus 9 ++ + +++ + +++ 2 2 ++ + +
S. simulans 9 ++ + ++ + ++ 2 (+) ++ + +
S. warneri 9 ++ 2 ++ + ++ 2 2 ++ + 2
S. xylosus 9 +++ +++ +++ ++ +++ 2 2 ++ + ++
aThe species was S. aureus unless stated otherwise.
bStrains were obtained from: 1Jean C. Lee, Channing Laboratory, Brigham and Women’s Hospital, Boston, MA, USA; 2ATCC 29740; 3Gerald B. Pier,
Channing Laboratory, Brigham and Women’s Hospital, Boston, MA, USA; 4Ambrose L. Cheung, Dartmouth Medical School, Hanover, NH, USA; 5Olaf
Schneewind, Department of Microbiology, University of Chicago, Chicago, IL, USA; 6Andreas Peschel, Medical Microbiology and Hygiene Department,
University of Tu¨bingen, Tu¨bingen, Germany; 7Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA), Chantilly, VA, USA; 8Yasunori
Tanji, Tokyo Institute of Technology, Yokohama, Japan (bovine mastitis isolate); and 9Max Paape, ARS, USDA, Beltsville, MD, USA (bovine mastitis isolate).
cFor 2638A, lysis zones were evaluated after overnight incubation at 378C (day 1), then further incubated at room temperature and evaluated again after
3 days (day 3+).
dEnzyme amounts causing a lysis zone: +++, 1 pmol; ++, 10 pmol; +, 100 pmol; (+) faint lysis zone observed at 100 pmol; 2, no lysis zone.
eANG133 and ANG144 showed 4-fold reduced susceptibility to lysostaphin in MIC assays compared with the WT Newman strain.15
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(a)
(b)
Figure 3. ESI–MS analysis of PGH cleavage sites. (a) ESI–MS spectra (m/z range 400–1000) of S. aureus Newman PG digested with four different dual
lytic domain endolysins. All spectra contain an identical dominant peak atm/z¼702. (b) Mass spectra (m/z range 650–750) of S. aureus SA113DtagO PG
after single digestion with full-length PGHs or double digestion with two different enzymes. Data were normalized to the highest peak (¼100%) within
the shown m/z range. Note that the numerous peaks in the P68+CHAP-K spectrum merely represent amplified background noise. (c) Portion of the
S. aureus PG (top) with dotted and cross-hatched arrows indicating cleavage sites of the amidase and CHAP/M23 endopeptidase domains,
respectively (cross-hatched arrows indicate that both the M23 domain of 2638A and the CHAP domains of the other seven endolysins exhibit
D-Ala-Gly endopeptidase activity). Domains are depicted with corresponding patterns in the schematics (bottom). Simultaneous digestion with both
catalytic domains yields the boxed fragment (A2QKG5) of m/z¼702, corresponding to the dominant peak in (a).
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702 peak (Figure 3b). By contrast, phiSH2 produced two larger
double-charged ions (m/z¼684 and 693), which presumably cor-
respond to the fragment Ala4-iGln2-Lys2-Gly10 (with andwithout a
water molecule) in addition to the (weaker) 702 peak, suggesting
incomplete digest by this relatively weak enzyme (Figure 1d). P68
digestion yielded only background signal, as expected from this sin-
gle lytic domain enzyme, which presumably produces fragments
comprising complete sugar strands; such strands would be too
large to be detected in this MS analysis (data not shown). To further
define the cleavage sites of the endopeptidase domains, double
digests were performed with each endolysin and the previously
reported CHAP-K deletion construct harbouring just the LysK
CHAP domain (D-Ala-Gly activity).19 In all spectra, the 702 peak
was dominant (except for P68) and no additional fragments com-
pared with the single digests were detected, confirming identical
cut sites for all of the dual lytic domain endolysins (Figure 3b).
P68/CHAP-K double digestion again produced no dominant
peaks, whereas after double digestion with P68 and a deletion con-
struct harbouring just the 2638A amidase domain22 the 702 peak
was detected in addition to the larger 684 fragment (product of
incomplete CHAP digestion), further confirming that the P68
CHAP domain exhibits D-Ala-Gly activity.
PGHs degrade staphylococcal biofilms
In viewof the significance of biofilms formedicine, agriculture and
food safety, the nine PGHs were compared for their potential to
degrade S. aureus SA113 biofilms cultured for 24 h in polystyrene
microtitre plates. Using this method, biofilms were formed pri-
marily at the bottoms of the wells, whereas the amount of biofilm
attached to the side walls was negligible. In a first series of experi-
ments with C-terminally 6×His-tagged PGHs in elution buffer,
most enzymes degraded the biofilms in a concentration-
dependent manner (Figure 4). Whereas LysK and lysostaphin
were effective at concentrations as low as 40–80 nM, phi11,
P68 and 2638A exhibited no measurable or only weak effects
under these conditions. In similar experiments with N-terminally
6×His-tagged proteins in PBS, phi11, 2638A and P68 markedly
degraded the biofilms at 160 nM, 310 nM and 2.5 mM, respect-
ively, whereas LysK, lysostaphin, Twort and phiSH2 were up to
one order of magnitude less effective under these alternative
conditions (Figure S4).
PGHs protect mice from systemic MRSA infection
To compare the in vivo efficacy of the nine PGHs and the antibiotics
oxacillin and vancomycin, BALB/c mice were inoculated intraper-
itoneally with 4×107 cfu of the MRSA strain NRS382 (a USA100
isolate) together with mucin as an immunosuppressant and trea-
ted after 30 min with PGHs (intraperitoneally; 200 mg/mouse),
antibiotics or buffer. Whereas only 25%–30% of the mice treated
with PBS, dialysis buffer or oxacillin survived after 48 h, 80a, phi11,
LysK, lysostaphin, 2638A, WMY and vancomycin protected 100%
of the animals from death (Figure 5a). Twort- or phiSH2-treated
mice showed less protection from systemic infection (50%–
60% survivors) and treatment with P68 (administered in 20%
instead of 10% glycerol and at 120 mg per mouse due to low
solubility) resulted in the least protection, with no survivors at
the end of the experiment. Average septicaemia scores deter-
mined over the period of 48 h were in good agreement with the
survival rates (Figure 5b; for scores of individual animals, see
Figure S5). While the health status of mice treated with buffers,
oxacillin or P68 rapidly deteriorated, reaching a moribund disease
state after 20 h, animals treated with 80a, phi11, LysK, lysosta-
phin, 2638A, WMY or vancomycin only showed temporary slight
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Figure 4. Biofilm-disrupting activity of staphylococcal PGHs. Biofilms of
S. aureus SA113 were grown in polystyrene 96-well plates for 24 h at
378C. After washing and incubation for 2.5 h at 378C with various
concentrations of C-terminally His-tagged PGHs in elution buffer or
elution buffer only as a control, wells were stained with crystal violet.
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illness and completely recovered by the end of the study. In the
cases of Twort and phiSH2, surviving mice developed clinical
signs of slight to moderate illness (Figure S5). When surviving
animals (after 48 h) were examined for presence of S. aureus in
the bloodstream, mice with bacteraemia were identified in the
buffer, antibiotics, phi11, 2638A, Twort and phiSH2 treatment
groups. No bacteria were detected in the blood of animals treated
with 80a, LysK, lysostaphin or WMY (Table 2).
Discussion
This is the first comparative study analysing enzymatic properties
and evaluating the antimicrobial/therapeutic potential of a
diverse collection of SH3b domain-containing staphylococcal
PGHs. In the past, poor expression and/or purification of some full-
length endolysins included in this study28,29 had hampered their
testing as antimicrobials and made it necessary to develop
strategies for enhancement of solubility.29,51Under the conditions
employed here, all nine PGHs were readily expressed and yielded
preparations of high purity. However, solubility of P68 rapidly
decreased with decreasing glycerol concentrations, reducing the
putative advantages conferred by this candidate therapeutic for
systemic administration, as demonstrated by the in vivo results
presented here. It should also be noted that the co-purification
of two enzymatically active (full-length and truncated) versions
of C-terminally 6×His-tagged 2638A impedes exact specific activ-
ity determinations of the full-length protein.22
Overall, the PGHs examined in this study exhibited lytic activity
against S. aureus in three different in vitro activity assays: zymo-
gram, turbidity reduction and plate lysis. It is apparent that the
three assays didnot always yield consistent results on a quantitative
level, an inconsistency previously reported and discussed.11,52 It has
also been proposed that small proteins and those with low cell wall
affinity exhibit higher activity in assays that rely on diffusion through
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Figure 5. Efficacy of PGHs and antibiotics in a mouse model of systemic MRSA infection. (a) Survival of mice infected intraperitoneally with MRSA and
subjected to different treatment regimens. Treatment groups listed on the right and corresponding survival curves are displayed in matching colours.
Numbers of animals in each group (N) are given in parentheses. Antibiotics are shown in italics and PGHs are underlined. Differences in survival rates
between PBS-treated control mice and animals treated with 80a, phi11, LysK, lysostaphin, 2638A, WMY or vancomycin were statistically significant
(P,0.02; Fisher’s exact test). (b) Average septicaemia scores of mice recorded for 48 h following infection. Scores for animals in different treatment
groups listed on the right (displayed in matching colours) correspond to the matrix shown in (c). (c) Composite matrix of septicaemia rating the
disease state of infected animals characterized by defined clinical signs.43
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a semi-solid matrix,53 which is consistent with the finding that P68
and lysostaphin produced themost intense lysis zones in the zymo-
gram (Figure 1c).
Whereas lysostaphin is a potent and well-characterized sta-
phylolytic agent with the ability to lyse staphylococcal species
other than S. aureus54 (Table 1), its application as a single thera-
peutic for treatment of staphylococcal infections is not supported
due to its documented susceptibility to bacterial resistance
development. However, the use of lysostaphin in combination
with other PGHs or as part of a chimeric PGH construct such as
PRF-11955 could circumvent this limitation. Resistance develop-
ment may explain why the majority of the SH3b domain-
containing staphylococcal phage endolysins have adopted a
dual-EAD architecture (two simultaneous mutations within a
highly conserved PG regionwould likely be required to evoke resist-
ance). Protein truncation analyses suggest that in the man-made
scenario of ‘lysis from without’, activity is usually ascribed to pri-
marily one of the two catalytic domains (mostly the CHAP
domain).19,22,23 Nonetheless, the results of our cut site determin-
ation suggest that both lytic domains are functional and that their
maintenance confers an evolutionary advantage on the phage.
This advantage might also include a synergistic effect of both
domains acting simultaneously, e.g. with one EAD increasing
accessibility to the cut site for the second catalytic domain.11
Particularly noteworthy and surprising (given the diverse amino
acid sequences and highly variable activities in functional assays)
is the finding that both the conserved CHAP domains and the
unrelated M23 domain of 2638A target the same PG bonds,
providing a prime example for convergent evolution among
phage endolysins. This finding provides the strongest support for
the notion that this combination of PGH activities (MurNAc-L-Ala
amidase and D-Ala-Gly endopeptidase) allows the most effective
destabilization of the cell wall in the context of progeny phage
particle release and raises the question of whether, over many
millennia of evolution, the phages have identified the cut sites
least susceptible to modification by the host, thus ensuring
longevity of the phage clade. The fact that the resistance-prone
lysostaphin harbours an M23 endopeptidase with different
(glycyl-glycine) activity supports this hypothesis.
Our plate lysis susceptibility tests represent the first time that
such an extensive collection of PGHs have been tested against a
panel of known cell wall mutants and revealed that this class of
enzymes is relatively unaffected by these surface structure altera-
tions. Increased susceptibility of the DtagO mutants can possibly
be explained by better accessibility of the PG substrate due to the
absence of teichoic acids in the cell walls of these strains and/or
the diminished cross-linking of PG from the DtagO mutants.45,56
It should be mentioned in this context that the glycine-rich
inter-peptide bridges in the PG have been suggested to be the tar-
gets for the SH3b CBDs of staphylococcal PGHs (not the teichoic
acids) and this has been demonstrated for lysostaphin’s SH3b
domain.11,57 It is important to note that the lyrA mutant
ANG144 showed reduced susceptibility not only to lysostaphin
but also to all endolysins. In contrast to the femAB mutant
ANG133, which features gross alterations of the pentaglycine
bridge responsible for lysostaphin tolerance, reduced susceptibil-
ity of ANG144 has been attributed mostly to other, as yet
unknownalterations of the cell envelope.15 A theoretically plausible
resistance mechanism for all cell wall-lytic agents acting from
without is themodification of secondary cell wall structures, creat-
ing steric hindrance and thereby reducing access to binding or cut
sites. Our resultswith the ANG144mutant demonstrate for the first
time that development of tolerance against endolysins is possible,
albeit likely at a lower frequency than for lysostaphin or antibiotics
that act inside the bacterial cell. Activity of the endolysins against
both coagulase-positive and coagulase-negative strains (Table 1)
was not unexpected, since the endolysin PG cleavage sites are con-
served throughout the genus Staphylococcus,14 and the SH3b
domains of several staphylococcal endolysins have been shown
to recognize strains from various staphylococcal species.11
The effectiveness of individual PGH constructs in treating sys-
temic infections caused by various bacterial pathogens has been
demonstrated in several studies (reviewed in Schmelcher et al.11)
and the results of our in vivo experiments with nine enzymes
corroborate these findings. Six out of nine PGHs tested showed
efficacy similar to vancomycin when administered as a single
dose (Figure 5) and four PGHs were able to prevent bacteraemia,
whereas MRSA was recovered from the blood of vancomycin-,
oxacillin- and buffer-treated animals (Table 2). It is of note that
all negative control animals (PBS-, dialysis buffer- and oxacillin-
treated) developed bacteraemia and that these three different
treatments yielded almost identical results in terms of survival
rates and average septicaemia scores, suggesting that the choice
of different administration routes and diluents did not adversely
affect the outcome of the experiment. Given the high amino
acid sequence diversity of the nine PGHs (,50% identical) and
the diverse results they yielded in the various in vitro assays
described here, it was not surprising that some of the enzymes
were less effective than others at protecting mice from systemic
MRSA infection. While the inefficacy of P68 can likely be attributed
Table 2. Recovery of MRSA from murine blood 48 h post-infection and
after different treatments
Treatment
Number of
mice
testeda
Percentage of
tested mice with
bacteraemiaa
Average MRSA
concentration in the
blood (log10 cfu/mL)
b
PBS 3 67% 2.48+0.31
Dialysis buffer 3 33% 2.55+0.71
Oxacillin 3 33% 2.61+0.81
Vancomycin 10 40% 2.18+0.11
80a 10 0% ,2
Phi11 10 10% 2.05+0.06
LysK 10 0% ,2
P68 0 NA NA
Lysostaphin 10 0% ,2
2638A 10 20% 2.10+0.08
Twort 5 60% 2.51+0.30
PhiSH2 6 83% 2.64+0.44
WMY 10 0% ,2
NA, not applicable.
aOnly blood from mice surviving after 48 h was tested.
bAverage concentrations are displayed as geometric means+SEM. The
detection limit in this experiment was 2 log10 cfu/mL. For calculating
means, individual mice with MRSA concentrations below the detection
limit were factored in with 2 log10 cfu/mL. For treatments where no
MRSA was detected in any of the tested mice, average concentrations
are displayed as ,2 log10 cfu/mL.
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to its low solubility, the low efficacy of phiSH2 is in good agree-
ment with the low activity of this enzyme in various in vitro assays
(Figures 1 and 2 and Table 1). The capability of PGHs investigated
here and in previous studies40,58 to degrade staphylococcal bio-
films is certainly encouraging, since biofilms are estimated to be
involved in .60% of bacterial infections in humans59 and signifi-
cantly contribute to the resistance of pathogens to conventional
treatment regimens.4,60 However, the results obtained here using
a static biofilm model need to be followed up by studies employ-
ing more sophisticated models.
In conclusion, this work represents the most comprehensive
comparison to date of: (i) staphylolytic antimicrobial activity;
(ii) enzymatic specificity; (iii) anti-biofilm activity; and (iv)
therapeutic potential, featuring a diverse group of SH3b domain-
containing PGH enzymes, including eight bacteriophage endoly-
sins and lysostaphin. Together with previous findings regarding
synergistic action, safety, near-species specificity, low immuno-
genicity and low frequency of resistant strain formation asso-
ciated with phage endolysins,10,11,61 these results support the
promise of these enzymes as antimicrobials to combat bacterial
infection/contamination by either CoNS or S. aureus, including
drug-susceptible and MDR strains. With regard to immunogen-
icity, several studies have found that although antibodies are pro-
duced against systemically administered endolysins, they do not
inactivate the PGHs in vivo. No adverse side effects have been
reported after systemic endolysin application in animal models
(reviewed by Fischetti10 and Schmelcher et al.11). One concern
associated with systemic endolysin administration is the possible
release of pro-inflammatory cellular debris, such as peptidoglycan
fragments and teichoic and lipoteichoic acids.10 Increased con-
centrations of pro-inflammatory cytokines were reported in
mice treated by continuous intravenous infusion of the strepto-
coccal phage endolysin Cpl-1, whereas reduced cytokine concen-
trations compared with untreated animals were detected when
the same enzymewas administered at 12 h intervals.62,63This dif-
ference was explained by the possibly higher degree of cell wall
fragmentation in the case of continuous infusion,10 which sug-
gests that repeated as opposed to continuous application of
endolysins may represent a more appropriate treatment regimen
when aiming to minimize problems associated with the release of
cellular debris. It is worth noting that our group of nine enzymes is
actually representative of multiple subgroups, totalling 60
SH3b-containing enzymes with .90% identity with at least one
of the nine lysins tested.18 The highly conserved targets resulting
from such a diverse set of protein sequences allow individual opti-
mizations (e.g. the unique plate lysis results for 2638A, the high
optimum ionic strength for phiSH2 activity, the high efficacy of
LysK and lysostaphin against biofilms under certain buffer condi-
tions, and the high activity of lysostaphin and P68 in semi-solid
matrices such as zymograms) and suggest that each enzyme
(or subgroup) may be best suited for a particular application
among the diverse antimicrobial needs of food safety, agriculture,
biotechnology and healthcare.
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